OUR INVESTMENTS

Compass Pathway PLC (CMPS)

COMPASS Pathways is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. COMPASS Pathway’s first clinical development program is researching investigational COMP360 psilocybin treatment for patients with treatment-resistant depression. The company wants to transform the patient experience in mental health care.

https://compasspathways.com/

IR@logoscapital.com

+1 (415) 801-4660 or +1 (415) 801-4670

Home
Team
Analytics
Investments
Investor Login
Privacy Policy

1 Letterman Drive, Building C, Suite C3-350, San Francisco, CA 94129

This website is for informational purposes only and does not constitute an offer to sell, a solicitation to buy, or a recommendation for any security; nor does it constitute an offer to provide investment advisory or other services by Logos Global Management LP (“Logos Capital”). Nothing contained on the website constitutes investment advice or offers any opinion with respect to the suitability of any security, and the views expressed on this website should not be taken as advice to buy, sell, or hold any security or as an endorsement of any security or company. In preparing the information contained in this website, Logos Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. Any views expressed on this website by Logos Capital were prepared based upon information, believed to be reliable, available to it at the time such views were written. Logos Capital makes no guarantees as to their accuracy or completeness. All information is subject to change and may quickly become unreliable for various reasons, including changes in market conditions or economic circumstances. By accessing this website, the reader agrees that he/she not copy, reproduce, republish, upload, post, transmit, alter, or distribute in any way material from this website in any manner inconsistent with the purposes for which it is offered without the prior written consent of Logos Capital.

bottom of page